Ralteglu 400 Tablet contains Raltegravir 400 mg, a potent HIV-1 integrase strand transfer inhibitor (INSTI) that prevents viral DNA integration into the host genome, a critical step in HIV replication. By blocking this process, Raltegravir effectively reduces viral replication and supports long-term viral suppression when used in combination antiretroviral therapy.
Clinically, Raltegravir is indicated for the treatment of HIV-1 infection in adults and pediatric patients, in combination with other antiretroviral agents. It plays a key role in first-line and treatment-experienced regimens, helping achieve rapid reduction in viral load and improvement in immunological markers such as CD4 cell counts.
The tablet formulation ensures precise dosing, consistent bioavailability, and reliable therapeutic outcomes, making it suitable for ART centers, hospitals, infectious disease clinics, and specialty pharmacies. Its oral administration supports treatment adherence, which is critical for successful long-term HIV management.
Ralteglu 400 Tablet contributes to sustained viral suppression, reduced risk of disease progression, and improved quality of life for people living with HIV. Its well-established efficacy and safety profile make it a trusted antiretroviral option in modern HIV treatment protocols under medical supervision.